Silpa Nuthalapati

Summary

Affiliation: Temple University
Country: USA

Publications

  1. pmc Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice
    Silpa Nuthalapati
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad Street, Philadelphia, PA 19140, USA
    J Pharm Biomed Anal 56:1117-20. 2011
  2. doi request reprint Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy
    Silpa Nuthalapati
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania 19140, USA
    Pharm Res 29:2499-511. 2012
  3. ncbi request reprint Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad St, Philadelphia, PA 19140, USA
    J Pharmacol Exp Ther 321:265-75. 2007

Detail Information

Publications3

  1. pmc Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice
    Silpa Nuthalapati
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad Street, Philadelphia, PA 19140, USA
    J Pharm Biomed Anal 56:1117-20. 2011
    ..ON01910 exhibited a clearance of 3.61±0.85 l/h/kg and a half life of 8.66±3.30 h at 50 mg/kg dose given I.V...
  2. doi request reprint Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy
    Silpa Nuthalapati
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania 19140, USA
    Pharm Res 29:2499-511. 2012
    ..Na, as a potential chemotherapeutic agent for brain tumors using a series of PK/PD studies, which led to the evaluation of its structural analog, ON013105, a prodrug of the more lipophilic product, ON013100...
  3. ncbi request reprint Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad St, Philadelphia, PA 19140, USA
    J Pharmacol Exp Ther 321:265-75. 2007
    ..In conclusion, several PK/PD factors contributing to the antitumor activity of the MD TMZ therapy have been identified and form a foundation for further investigations of low-dose TMZ regimens...